Gene Therapy for Pyruvate Kinase Deficiency (PKD)

  • STATUS
    Recruiting
  • End date
    Mar 29, 2023
  • participants needed
    6
  • sponsor
    Rocket Pharmaceuticals Inc.
Updated on 17 February 2022

Summary

This is an open-label Phase I trial to evaluate the safety of a hematopoietic cell-based gene therapy for patients with Pyruvate Kinase Deficiency (PKD).

Description

Autologous hematopoietic stem cells from mobilized peripheral blood will be transduced ex vivo (outside the body) with a lentiviral vector carrying a correct copy of the deficient PKD gene. The corrected stem cells will be infused intravenously back to the patient with the goal of correcting the hematological manifestations of the disease.

Details
Condition Pyruvate Kinase Deficiency
Treatment RP-L301
Clinical Study IdentifierNCT04105166
SponsorRocket Pharmaceuticals Inc.
Last Modified on17 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

PKD diagnosis with a confirmed PKLR mutation
Age 18 years old and <50 years for the initial 2 patients enrolled; 12-17 years for the next 2 patients; 8-11 years for the final 2 patients
History of severe, transfusion-dependent anemia, defined as
At least 6 red blood cell transfusion episodes over a prior 12-month period, or at least 3 red blood cell transfusion episodes per year over 2 prior years (in the absence of precipitating events such as infection or surgery) and
Hb levels <9.5 g/dL in the previous 12 months despite prior splenectomy. OR for adult patients (age 18 years) and older pediatric patients (age 12-17)
Hb levels <8.0 g/dL in the absence of transfusions (documented during 2 or more assessments during the prior 1-2 years) regardless of transfusion requirements
Adequate cardiac, pulmonary, renal and hepatic function, as detailed in relevant exclusion criteria
Availability of detailed medical records, including transfusion requirements, for at least the prior 2 years
Willing and able to read and correctly understand the patient information sheet and provide consent (or informed assent for minors) regarding study participation
Negative serum pregnancy test for female patients of childbearing potential

Exclusion Criteria

Presence of other known causes of hemolysis (in addition to PKD). Patients with concurrent G6PD deficiency diagnosed during pre-study evaluation may be considered for eligibility if in the opinion of the Investigator, the hemolytic anemia is the result of PKD and the G6PD deficiency is considered an incidental finding
A venous thromboembolic event (VTE; i.e., pulmonary embolism or deep vein thrombosis) or arteriothromboembolic event (ATE; including unstable angina, myocardial infarction, stroke or transient ischemic attack) during the prior 12 months
Any evidence of severe iron overload that, per Investigator discretion, warrants exclusion
Evidence of bridging fibrosis, cirrhosis or active hepatitis on liver biopsy. Liver biopsy is required when liver iron concentration (LIC) is 15 mg/g on T2 magnetic resonance imaging (MRI) of liver. If a liver biopsy has been performed less than 6 months prior to enrollment, it does not need to be repeated
Significant medical conditions including documented HIV infection, active viral hepatitis, poorly-controlled hypertension, pulmonary hypertension cardiac arrhythmia or congestive heart failure; pulmonary hypertension or ATEs (including stroke or myocardial infarction) within the 6 prior months
Active hematologic or solid organ malignancy, not including non-melanoma skin cancer or another carcinoma in situ. Patients with previously resected solid organ malignancies or definitively treated hematologic malignancies may be eligible if there has been no evidence of active malignancy during the prior 3 years
Uncontrolled seizure disorder
Cardiac T2<10 ms by magnetic resonance imaging (MRI) or left ventricular ejection fraction (LVEF) <45% by echocardiogram or multiple gated acquisition (MUGA) scanning
Hepatic dysfunction as defined by: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 the upper limit of normal.(ULN)
Renal dysfunction as defined as serum creatinine > ULN. Patients with creatinine above ULN may be eligible pending documentation of a GFR 60 mL/min/1.73m2 as calculated by the Modification of Diet in Renal Disease equation (Stevens 2006), the revised Schwartz formula (for patients under 18 years old) (Schwartz 2009), or 24-hour urine collection
Pulmonary dysfunction as defined by either
Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection) or
Oxygen saturation (by pulse oximetry) <90%
Any medical or other contraindication for both leukapheresis and BM harvest procedure as determined by the treating Investigator
Any medical or psychiatric condition that in the opinion of the Investigator renders the subject unfit for trial participation or at higher than acceptable risk for participation
Poor functional status, evidenced by Karnofsky Index <70 in adults or Lansky <70 in children
Participation in another clinical trial with an investigational drug within 14 days before the informed consent signature. Participation in observational studies is allowed
Pregnant women or women with a positive serum pregnancy test at screening or breast feeding or planning to become pregnant within the next 24 months. Women not willing to use highly effective contraceptive methods during the complete study period
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note